Erenumab response spectrum in episodic migraine and response threshold subgroup analysis


  • Individuals with episodic migraine (EM) who received erenumab achieved greater reductions in monthly migraine days (MMD) compared with placebo; those who reached the ≥50%, ≥75%, or 100% response thresholds exhibited greater reductions in migraine-specific medication days (MSMD) and migraine days, and improvements in disability compared with the overall population.

Why this matters

    Typically, the primary endpoint of clinical trials have focused on migraine preventative therapy is the mean reduction in MMD, however, the wide range of efficacy in people may be more accurately captured by reporting the full spectrum of responses.